Additional evidence that MYC dysregulates glutamine metabolism was provided by a recent study that found elevation of the glutamine synthetase (Glul) enzyme and glutamine abundance in a transgenic mouse model of dual MYC and KRAS-driven pancreatic cancer, compared to tumors driven by KRAS alone (Bott et al., 2015). Here, KRAS is linked to pancreatic neoplasm.